Led · Grant · Jun 2026

BTRY is a 2023 spinout developing ultrathin thin-film solid-state batteries that replace liquid electrolytes with solid materials to combine energy storage and high power delivery. The company employs a solvent-free vacuum roll-to-roll coating process derived from the semiconductor industry to enable scalable, cost-efficient production. BTRY targets applications across industrial use cases, the Internet of Things, medical technology, and wearable devices. It plans to industrialize its technology and establish what it describes as Europe’s first industrial plant for thin-film solid-state batteries, aiming to produce millions of units per year. The only financial detail reported in the article is the recent €2.2 million EIC Accelerator grant to support those plans.

Participated · Seed · Jun 2026

OurMind builds AI tools for healthcare providers to automate administrative tasks and support clinicians across the consultation lifecycle. Its first product, Notes, converts consultation conversations into medical documentation and is currently used by over 300 general practices and 14 hospitals. The company is expanding its platform with features for consultation preparation, administrative support, and patient communication, and is developing a broader AI platform that adapts to individual clinicians' needs. Founded by former orthopaedic surgeon Paul Koning and backed by healthcare professionals, OurMind works closely with hospitals to ensure safe, practical implementation of generative AI in clinical settings. The recent €2.1 million funding led by 4impact capital will be used to scale the platform and meet increasing demand from healthcare organisations.

Led · Grant · May 2026

NETRIS Pharma is a clinical-stage biotech focused on targeting the netrin-1/dependence receptor axis to counteract treatment resistance in cancer. Its lead investigational asset, NP137, is a first-in-class humanized monoclonal antibody that blocks netrin-1 and is designed to inhibit epithelial-to-mesenchymal transition (EMT). NP137 is in clinical development across multiple solid tumor indications, including pancreatic ductal adenocarcinoma, hepatocellular carcinoma and head and neck squamous cell carcinoma. The company is launching a Horizon Europe-funded randomized Phase 2b trial in HNSCC, conducted in partnership with cooperative clinical groups GORTEC and TTCC and led by Dr. Jérôme Fayette. NETRIS was co-founded by scientists who pioneered netrin-1 and dependence receptor biology and lists Lyon, France and Geneva, Switzerland in its announcement. The company emphasizes a precision oncology strategy incorporating translational biomarker endpoints to inform future regulatory discussions.

Led · Grant · May 2026

Adamo Foods develops whole-cut mycelium-based meat alternatives using a triple-patented submerged fungal fermentation process to create long, densely grouped mycelium fibres that mimic muscle structure. Its flagship product is a five-ingredient mycelium steak that the company says contains all essential amino acids and achieves a protein digestibility score of 0.99. The startup highlights rapid production (mycelium doubles every ~4 hours), lower land use and substantially reduced emissions—claiming its product is 93% lower in carbon emissions than beef—and aims for price parity at launch. Adamo is scaling from in-house pilot production to a demo plant (>5,000 litres) and targets 50,000 litres within three years, while engaging partners for commercial manufacturing. Founded in 2021, the company has raised about €5M from investors and participated in EIT Food’s RisingFoodStars programme, and plans an initial commercial rollout in UK foodservice.

Participated · Series A · May 2026

Founded in 2020 as a spin-off from the University of Siegen, eleQtron develops trapped-ion quantum processors based on its proprietary MAGIC (Magnetic Gradient Induced Coupling) technology that enables microwave-based control of qubits. The company combines research-driven innovation with a stated focus on industrial scaling and commercialisation of quantum systems. eleQtron plans to scale production capacity and expand cloud-based access to its systems to support industrial deployment. Its near-term product and engineering roadmap centers on advancing its hardware platform and making systems accessible via the cloud. The company employs more than 100 people and has partnerships with leading European research and computing centres. Recent funding and grants are intended to accelerate its shift from laboratory development toward industrially usable quantum infrastructure.